Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA. 2001;285(18):2370.

Article  PubMed  CAS  Google Scholar 

Kattelus H, Kesäniemi YA, Huikuri H, Ukkola O. Cancer increases the risk of atrial fibrillation during long-term follow-up (OPERA study). PLoS ONE. 2018;13(10):e0205454.

Article  PubMed  PubMed Central  Google Scholar 

Suero-Abreu GA, Ellinor PT. Atrial fibrillation in patients with cancer: a persistent and increasing challenge. JACC CardioOncol. 2023;5(2):230–2.

Article  PubMed  PubMed Central  Google Scholar 

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49.

Article  PubMed  Google Scholar 

D’Souza M, Smedegaard L, Madelaire C, et al. Incidence of atrial fibrillation in conjunction with breast cancer. Heart Rhythm. 2019;16(3):343–8.

Article  PubMed  Google Scholar 

Guha A, Fradley MG, Dent SF, et al. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. Eur Heart J. 2022;43(4):300–12.

Article  PubMed  Google Scholar 

Rhea I, Burgos PH, Fradley MG. Arrhythmogenic anticancer drugs in cardio-oncology. Cardiol Clin. 2019;37(4):459–68.

Article  PubMed  Google Scholar 

Apte N, Dherange P, Mustafa U, et al. Cancer radiation therapy may be associated with atrial fibrillation. Front Cardiovasc Med. 2021;8:610915.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ahmad J, Thurlapati A, Thotamgari S, et al. Anti-cancer drugs associated atrial fibrillation—an analysis of real-world pharmacovigilance data. Front Cardiovasc Med. 2022;9:739044.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yao X, Hu Q, Liu X, et al. Atrial fibrillation and breast cancer-vicious twins? A systematic review and meta-analysis. Front Cardiovasc Med. 2023;10:1113231.

Article  PubMed  PubMed Central  Google Scholar 

Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63(10):945–53.

Article  PubMed  Google Scholar 

Mauro E, Lucà F, Tetta C, et al. Breast cancer and atrial fibrillation. J Clin Med. 2022;11(5):1417.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Madnick DL, Fradley MG. Atrial fibrillation and cancer patients: mechanisms and management. Curr Cardiol Rep. 2022;24(10):1517–27.

Article  PubMed  Google Scholar 

Menichelli D, Vicario T, Ameri P, et al. Cancer and atrial fibrillation: epidemiology, mechanisms, and anticoagulation treatment. Prog Cardiovasc Dis. 2021;66:28–36.

Article  PubMed  Google Scholar 

Chu G, Versteeg HH, Verschoor AJ, et al. Atrial fibrillation and cancer—an unexplored field in cardiovascular oncology. Blood Rev. 2019;35:59–67.

Article  PubMed  Google Scholar 

Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006;118(5):555–68.

Article  PubMed  CAS  Google Scholar 

Semeraro GC, Meroni CA, Cipolla CM, Cardinale DM. Atrial fibrillation after lung cancer surgery: prediction, prevention and anticoagulation management. Cancers (Basel). 2021;13(16):4012.

Article  PubMed  CAS  Google Scholar 

Zhang L, Li X, Wu H, Luo J. Risk factors associated with atrial fibrillation following lung cancer surgery: a multi-center case-control study. Asian J Surg. 2024;47(1):176–83.

Article  PubMed  Google Scholar 

National Cancer Institute. Breast cancer treatment (PDQ®)–health professional version. Bethesda (MD): National Cancer Institute; [updated 2024 Jun 15; cited 2024 Jun 15]. Available from: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023;401(10384):1277–92.

Geyer CE, Blum JL, Yothers G, et al. Long-term follow-up of the anthracyclines in early breast cancer trials (USOR 06–090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]). JCO. 2024;42(12):1344–9.

Article  Google Scholar 

Ho I, Wong CK, Wong YK, et al. Aromatase inhibitor therapy increases the risk of new-onset atrial fibrillation in patients with breast cancer. JACC Asia. 2024;4(2):150–60.

Article  PubMed  Google Scholar 

Yu KD, Ye FG, He M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020;6(9):1390.

Article  PubMed  Google Scholar 

Yang X, Li X, Yuan M, et al. Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms. Front Pharmacol. 2018;9:1058.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801.

Article  PubMed  Google Scholar 

Font J, Milliez P, Ouazar AB, Klok FA, Alexandre J. Atrial fibrillation, cancer and anticancer drugs. Arch Cardiovasc Dis. 2023;116(4):219–26.

Article  PubMed  Google Scholar 

Burashnikov A. Atrial fibrillation induced by anticancer drugs and underling mechanisms. J Cardiovasc Pharmacol. 2022;80(4):540–6.

Article  PubMed  CAS  Google Scholar 

Yuan M, Tse G, Zhang Z, et al. The incidence of atrial fibrillation with trastuzumab treatment: a systematic review and meta-analysis. Cardiovasc Ther. 2018;36(6):e12475.

Article  PubMed  Google Scholar 

Wu WC, Huang CC, Tsai YF, et al. The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis. Breast Cancer Res Treat. 2023;198(1):113–22.

Article  PubMed  CAS  Google Scholar 

Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136(21):2085–7.

Article  PubMed  Google Scholar 

Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447–58.

Article  PubMed  CAS  Google Scholar 

Recht A, Comen EA, Fine RE, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. J Clin Oncol. 2016;34(36):4431–42.

Article  PubMed  Google Scholar 

Jacobs JEJ, L’Hoyes W, Lauwens L, et al. Mortality and major adverse cardiac events in patients with breast cancer receiving radiotherapy: the first decade. J Am Heart Assoc. 2023;12(8):e027855.

Article  PubMed  PubMed Central  Google Scholar 

Grewal US, Patel HP, Sheth AR, Beedupalli K, Dominic P. Impact of radiation on inpatient outcomes in patients with breast cancer and atrial fibrillation: a nationwide analysis. Heart Rhythm. 2022;19(7):1210–1.

Article  PubMed  Google Scholar 

Avula V, Sharma G, Kosiborod MN, et al. SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction. JACC Heart Fail. 2024;12(1):67–78.

Article